Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$161.01 - $317.85 $7.35 Million - $14.5 Million
45,673 Added 4.92%
974,643 $308 Million
Q3 2023

Nov 14, 2023

BUY
$164.66 - $218.08 $18.7 Million - $24.8 Million
113,684 Added 13.94%
928,970 $157 Million
Q2 2023

Aug 14, 2023

SELL
$176.32 - $240.22 $32 Million - $43.5 Million
-181,249 Reduced 18.19%
815,286 $177 Million
Q1 2023

May 15, 2023

BUY
$161.33 - $204.36 $3.37 Million - $4.26 Million
20,858 Added 2.14%
996,535 $181 Million
Q4 2022

Feb 14, 2023

BUY
$191.53 - $236.82 $18.9 Million - $23.4 Million
98,832 Added 11.27%
975,677 $192 Million
Q3 2022

Nov 15, 2022

SELL
$123.79 - $277.42 $38.6 Million - $86.4 Million
-311,592 Reduced 26.22%
876,845 $197 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $15.2 Million - $23.2 Million
161,930 Added 15.77%
1,188,437 $150 Million
Q1 2022

May 16, 2022

BUY
$98.9 - $132.37 $18.5 Million - $24.8 Million
187,142 Added 22.3%
1,026,507 $130 Million
Q4 2021

Feb 14, 2022

SELL
$110.64 - $159.4 $2.55 Million - $3.67 Million
-23,024 Reduced 2.67%
839,365 $110 Million
Q3 2021

Nov 15, 2021

BUY
$101.2 - $125.87 $13.8 Million - $17.1 Million
136,202 Added 18.76%
862,389 $105 Million
Q2 2021

Aug 16, 2021

BUY
$107.45 - $135.95 $2.06 Million - $2.6 Million
19,135 Added 2.71%
726,187 $82.8 Million
Q1 2021

May 17, 2021

SELL
$95.46 - $133.08 $6.45 Million - $8.99 Million
-67,527 Reduced 8.72%
707,052 $85 Million
Q4 2020

Feb 16, 2021

SELL
$75.23 - $109.23 $1.89 Million - $2.74 Million
-25,057 Reduced 3.13%
774,579 $78.7 Million
Q3 2020

Nov 10, 2020

BUY
$71.31 - $109.74 $2.73 Million - $4.2 Million
38,290 Added 5.03%
799,636 $61.8 Million
Q2 2020

Aug 14, 2020

BUY
$62.14 - $117.21 $33.1 Million - $62.5 Million
533,111 Added 233.58%
761,346 $84.9 Million
Q1 2020

May 11, 2020

BUY
$60.41 - $115.92 $13.8 Million - $26.5 Million
228,235 New
228,235 $16.4 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.